Intellipharmaceutics International Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Intellipharmaceutics International Inc (IPCIF) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Intellipharmaceutics International Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 0M vs 284,858M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+407.6% annualized vs trailing 12 months), vs decelerating (-6.7%) for its tracked peer group.
- Profitability: Its -1,056.2% net margin compares with 22.2% for the peer group.
- Peer revenue share: Intellipharmaceutics International Inc accounted for 0.0% of combined revenue among its tracked peer group.
- Peer differentiation: Revenue per employee of $0.00M compares with $0.95M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
IPCIF Sales vs. its Competitors, Q4 2022
With a net margin of -1,056.18 %, Intellipharmaceutics International Inc reported lower profitability than its competitors (22.23 %).
Intellipharmaceutics International Inc generated 0.00 % of the combined sales of its peer group.
API endpoints for this dataset
Intellipharmaceutics International Inc vs. its Competitors, Q4 2022
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Intellipharmaceutics International Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Intellipharmaceutics International Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Intellipharmaceutics International Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Intellipharmaceutics International Inc's competitor groups requires a Commercial License.
Intellipharmaceutics International Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Intellipharmaceutics International Inc | - | - | - | Yes |
| Competitors combined (57) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
IPCIF Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Eton Pharmaceuticals Inc | 282.9% | Outperformed |
| 2 | Avadel Pharmaceuticals Plc | 282.9% | Outperformed |
| 3 | Evoke Pharma Inc | 282.9% | Outperformed |
| 4 | Ironwood Pharmaceuticals inc | 282.9% | Outperformed |
| 5 | Cumberland Pharmaceuticals Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Intellipharmaceutics International Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Intellipharmaceutics International Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Intellipharmaceutics International Inc | - | 0.07 |
| Abbvie Inc | 520,773.08 | 66,014.00 |
| Amgen Inc | 254,015.58 | 38,903.00 |
| Pfizer Inc | 168,849.36 | 63,625.00 |
| Vertex Pharmaceuticals Inc | 139,821.53 | 12,951.60 |
| Regeneron Pharmaceuticals Inc | 96,735.94 | 16,896.20 |
| SUBTOTAL | 1,370,788.48 | 286,234.27 |
Sign in to see all competitors of Intellipharmaceutics International Inc .
Sources: Intellipharmaceutics International Inc's official press releases and company reports; CSIMarket.com's market research; and the company reports and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Intellipharmaceutics International Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Intellipharmaceutics International Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amgen Inc | Reportable 100.00 % |
| Pfizer Inc | U.S. Commercial Division 58.35 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Teva Pharmaceutical Industries Limited | United States 42.55 % |
| Viatris Inc | Developed Markets 59.34 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Intellipharmaceutics International Inc .
Intellipharmaceutics International Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Intellipharmaceutics International Inc | - | 1,315 | -57,848 |
| Abbvie Inc | 520,773 | 1,158,140 | 181,509 |
| Amgen Inc | 254,016 | 2,992,538 | 722,385 |
| Pfizer Inc | 168,849 | 848,333 | 54,160 |
| Vertex Pharmaceuticals Inc | 139,822 | 31,979,259 | 9,817,037 |
| Regeneron Pharmaceuticals Inc | 96,736 | 1,096,444 | 312,615 |
| PEERS TOTAL | 1,370,788 | 953,745 | 76,253 |
Sign in to see all peers for Intellipharmaceutics International Inc .
Intellipharmaceutics International Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Intellipharmaceutics International Inc | United State 45.16 % |
| Pfizer Inc | United States 63.93 % |
| Vertex Pharmaceuticals Inc | United States 63.04 % |
| Teva Pharmaceutical Industries Limited | Europe 30.49 % |
| Horizon Therapeutics Public Limited Company | United States 97.76 % |
| Catalent Inc | North America 64.32 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Intellipharmaceutics International Inc .
Intellipharmaceutics International Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (446 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.00 % | 37.92 % (avg) | -37.9 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -6.30 % (avg) | - |
| Capital Intensity (Capex / Revenue) | - | 7.51 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Intellipharmaceutics International Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2019 | 2020 | 2022 |
|---|---|---|---|
| Revenue Growth | 103.21 % | - | - |
| Operating Margin | - | - | - |
| Return on Invested Capital | - | - | - |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Intellipharmaceutics International Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+407.6% annualized vs trailing 12 months).
Weaknesses
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (34.50 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-6.7% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Intellipharmaceutics International Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Intellipharmaceutics International Inc | 0.01 | 0.05 | - |
| Abbvie Inc | 0.19 | 0.79 | - |
| Amgen Inc | 0.49 | 1.31 | 5.27 |
| Pfizer Inc | 0.04 | 1.27 | 0.72 |
| Vertex Pharmaceuticals Inc | 1.30 | 2.83 | 0.06 |
| Regeneron Pharmaceuticals Inc | 0.58 | 3.56 | 0.06 |
Sign in to see all peers for Intellipharmaceutics International Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Intellipharmaceutics International Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Intellipharmaceutics International Inc | Q1 2022 | - | - |
| Abbvie Inc | Q3 2026 | +10.3 % | +2,143.6 % |
| Amgen Inc | Q3 2026 | +8.5 % | +20.1 % |
| Pfizer Inc | Q3 2026 | -0.4 % | -8.7 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +11.8 % | -39.6 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +36.3 % | +33.5 % |
| PEERS TOTAL | 0.0 % | - |
Sign in to see all peers for Intellipharmaceutics International Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Intellipharmaceutics International Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Intellipharmaceutics International Inc | Q1 2022 | - | - |
| Abbvie Inc | Q3 2026 | -19.2 % | -21.0 % |
| Amgen Inc | Q3 2026 | -9.5 % | +34.6 % |
| Pfizer Inc | Q3 2026 | -3.5 % | -4.8 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +26.8 % | -4.4 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +104.1 % | +49.1 % |
Sign in to see all peers for Intellipharmaceutics International Inc .
Intellipharmaceutics International Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Intellipharmaceutics International Inc | - | - | - |
| Abbvie Inc | 7.48% | 12.87% | - |
| Amgen Inc | 10.02% | 13.64% | 85.59% |
| Pfizer Inc | 1.98% | 2.34% | 4.62% |
| Vertex Pharmaceuticals Inc | 14.16% | 16.63% | 20.08% |
| Regeneron Pharmaceuticals Inc | 11.50% | 13.00% | 15.07% |
Sign in to see all peers for Intellipharmaceutics International Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Intellipharmaceutics International Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Intellipharmaceutics International Inc | - | - |
| Abbvie Inc | 50.58 | 7.89 |
| Amgen Inc | 26.97 | 6.53 |
| Pfizer Inc | 41.79 | 2.65 |
| Vertex Pharmaceuticals Inc | 35.32 | 10.80 |
| Regeneron Pharmaceuticals Inc | 20.26 | 5.73 |
| PEERS AVERAGE | 59.91 | 4.79 |
Sign in to see all peers for Intellipharmaceutics International Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.